BayPAT’s Licensee Recardio already in Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin in Europe and USA

BayPAT, a service provider offering services in the area of technology transfer, IP management and commercialisation, today announced that its licensee Recardio is already in the Phase 2 study for regenerative therapy in early recovery post-myocardial infarction in Europe and Read More

Biological hazards – VelaLabs is prepared to support you

Originator companies and generic/biosimilar companies in the (bio)pharmaceutical industry are working more and more with different biological materials of animal or human origin. Cell lines from bacteria, plants, animal and/or humans as well as viruses are used in the development Read More

First Patients Enrolled into the MOCA I Trial

CorFlow Therapeutics AG ("CorFlow") today announced that the first two patients have been enrolled into the First-in-Man (FIM) MOCA I clinical trial.  The first MOCA (Microvascular Obstruction with the CoFITM System Assessment) trial is a safety and feasibility trial assessing the CorFlow Controlled Read More

Restructuring of Romanian health authority breathes new life into clinical trials in Romania

Over the past years pharmaceutical companies had to face unpredictable and increasingly long response times for clinical trial approvals in Romania. As a result, the number of clinical trials in Romania clearly decreased. Now, the National Agency of Medicines and Read More

apceth will operate as the commercial manufacturer in Europe for ZyntegloTM, bluebird bio’s gene therapy for β-thalassemia

apceth Biopharma GmbH, a leading company for the manufacturing of cell and gene therapeutics, will operate as the commercial manufacturer in Europe for ZyntegloTM, a product of bluebird bio. Yesterday the European Commission (EC) has granted conditional marketing authorisation for Read More

Richard Wolf subsidiary RIWOspine installs new business structure in Japan

RIWOspine GmbH, headquartered in Knittlingen, Germany, is one of the world’s leading suppliers of endoscopic systems for minimally invasive surgery and interventional spinal pain therapy. The strategic takeover of the local trading partner and the installation of an independent business Read More

QIAGEN’s QuantiFERON®-TB Access development program gains recognition from United Nations initiative for health innovation

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON®-TB Access, a new solution under development for diagnosis of latent tuberculosis (TB) infection in low-resource regions with a high disease burden of tuberculosis, will be recognized by the Read More

QIAGEN launches first FDA-approved companion diagnostic using FGFR alterations to help guide the treatment of metastatic urothelial cancer

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of its novel therascreen® FGFR RGQ RT-PCR Kit (therascreen FGFR Kit) as a companion diagnostic to help guide the use of the newly approved FGFR kinase inhibitor, Read More